BR112013006594A2 - composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto - Google Patents
composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um compostoInfo
- Publication number
- BR112013006594A2 BR112013006594A2 BR112013006594A BR112013006594A BR112013006594A2 BR 112013006594 A2 BR112013006594 A2 BR 112013006594A2 BR 112013006594 A BR112013006594 A BR 112013006594A BR 112013006594 A BR112013006594 A BR 112013006594A BR 112013006594 A2 BR112013006594 A2 BR 112013006594A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hydrogen atom
- disorder
- atom
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 108050000742 Orexin Receptor Proteins 0.000 abstract 2
- 102000008834 Orexin receptor Human genes 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 2
- -1 cyclopropane compound Chemical class 0.000 abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto. um composto ciclopropano representado pela fórmula seguinte (a) ou um sal farmaceuticamente aceitável do mesmo exibe antagonismo de receptores da orexina, e assim tem um potencial de utilidade para o tratamento de um distúrbio do sono para o qual é eficaz anagonismo de receptores da orexina, por exemplo, insônia: em que q representa -ch- ou um átomo de nitrogênio, r~ 1a~ e r~ 1b~. cada um independentemente, representam um grupo c~ 1-6~ alquila e afins, r~ 1c~representa um átomo de hidrogênio e afins, r~ 2a~, r~ 2b~ , r~ 2c~ e r~ 2d~ cada um independentemente, representam um átomo de hidrogênio, um átomo de halogênio, um grupo c[ 1-6~alquila e afins, r~ 3a~, r~ 3b~ e r~ 3c~, cada um independentemente, representam um átomo de hidrogênio, um átomo de halogênio e afins e r~ 3d~ representa um átomo de hidrogênio e afins.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38534210P | 2010-09-22 | 2010-09-22 | |
| JP2010-211629 | 2010-09-22 | ||
| JP2010211629 | 2010-09-22 | ||
| US61/385,342 | 2010-09-22 | ||
| PCT/JP2011/071325 WO2012039371A1 (ja) | 2010-09-22 | 2011-09-20 | シクロプロパン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013006594A2 true BR112013006594A2 (pt) | 2016-06-21 |
| BR112013006594B1 BR112013006594B1 (pt) | 2021-08-17 |
Family
ID=45873858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013006594-0A BR112013006594B1 (pt) | 2010-09-22 | 2011-09-20 | Composto ciclopropano antagonista de receptor da orexina e composição farmacêutica |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8268848B2 (pt) |
| EP (1) | EP2626350B1 (pt) |
| JP (1) | JP4944286B1 (pt) |
| KR (1) | KR101458007B1 (pt) |
| CN (1) | CN103153963B (pt) |
| AR (1) | AR083060A1 (pt) |
| AU (1) | AU2011304285B2 (pt) |
| BR (1) | BR112013006594B1 (pt) |
| CA (1) | CA2811895C (pt) |
| CL (1) | CL2013000784A1 (pt) |
| DK (1) | DK2626350T3 (pt) |
| ES (1) | ES2540851T3 (pt) |
| IL (1) | IL225437A (pt) |
| JO (1) | JO2990B1 (pt) |
| MA (1) | MA34609B1 (pt) |
| MX (1) | MX2013003218A (pt) |
| MY (1) | MY160969A (pt) |
| NZ (1) | NZ609313A (pt) |
| PE (1) | PE20131162A1 (pt) |
| PL (1) | PL2626350T3 (pt) |
| PT (1) | PT2626350E (pt) |
| RS (1) | RS54101B1 (pt) |
| RU (1) | RU2571414C2 (pt) |
| SG (1) | SG188585A1 (pt) |
| SI (1) | SI2626350T1 (pt) |
| TW (1) | TWI516484B (pt) |
| UA (1) | UA108510C2 (pt) |
| WO (1) | WO2012039371A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2733750T3 (es) | 2012-02-17 | 2019-12-02 | Eisai R&D Man Co Ltd | Métodos y compuestos útiles en la síntesis de antagonistas del receptor de orexina-2 |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| KR102325655B1 (ko) | 2014-08-06 | 2021-11-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피리미딘-1-올 화합물의 제조 방법, 및 이의 중간체 |
| KR102444608B1 (ko) * | 2014-10-23 | 2022-09-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 불면증을 치료하기 위한 조성물 및 방법 |
| CA3001658A1 (en) | 2015-10-29 | 2017-05-04 | University Of Tsukuba | Morphinan derivative and medical usage thereof |
| US11096941B2 (en) | 2016-05-12 | 2021-08-24 | Eisai R&D Management Co.. Ltd. | Methods of treating circadian rhythm sleep disorders |
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| EP3971164A4 (en) | 2019-05-15 | 2023-01-04 | Eisai R&D Management Co., Ltd. | METHOD AND COMPOUND FOR THE PREPARATION OF OREXIN-2 RECEPTOR ANTAGONISTS AND LMBOREXANT WITH LOW IMPURITIES |
| MX2021016090A (es) * | 2019-06-26 | 2022-02-03 | Eisai R&D Man Co Ltd | Lemborexant para el tratamiento de problemas del sueño. |
| JP2023506025A (ja) | 2019-12-11 | 2023-02-14 | テバ チェコ インダストリーズ エス．アール．オー． | レンボレキサントの固体形態 |
| MX2022007304A (es) | 2019-12-20 | 2022-08-22 | Eisai R&D Man Co Ltd | Uso de lemborexant para tratamiento del insomnio. |
| US20230103250A1 (en) | 2020-01-16 | 2023-03-30 | Eisai R&D Management Co., Ltd. | Drug substance of lemborexant and medicinal composition comprising same |
| WO2021205648A1 (ja) * | 2020-04-10 | 2021-10-14 | 国立大学法人東海国立大学機構 | 精神障害患者の客観的睡眠評価方法 |
| CN117769423A (zh) | 2021-07-26 | 2024-03-26 | 卫材R&D管理有限公司 | 莱博雷生用于在治疗与神经系统变性疾病相关的不规律睡眠觉醒节律紊乱和昼夜节律性睡眠障碍的方法中使用 |
| CN118871427A (zh) * | 2022-03-25 | 2024-10-29 | 浙江华海药业股份有限公司 | 一种莱博雷生及其中间体的制备方法 |
| WO2023178702A1 (zh) * | 2022-03-25 | 2023-09-28 | 浙江华海药业股份有限公司 | 莱博雷生及其中间体化合物的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06328057A (ja) | 1993-05-26 | 1994-11-29 | Sanyo Electric Co Ltd | 厨芥処理装置 |
| EP0828751A4 (en) | 1995-05-05 | 1999-01-20 | Human Genome Sciences Inc | HUMAN NEUROPEPTIDE RECEPTOR |
| KR100499106B1 (ko) * | 1996-12-10 | 2005-07-01 | 브리스톨-마이어즈 스퀴브 컴페니 | 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제 |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6001963A (en) | 1996-12-17 | 1999-12-14 | Smithkline Beecham Corporation | Ligands of the neuropeptide receptor HFGAN72 |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| BRPI0508263B8 (pt) | 2004-03-01 | 2021-05-25 | Idorsia Pharmaceuticals Ltd | derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina |
| MX2007003377A (es) * | 2004-09-23 | 2007-05-10 | Pfizer Prod Inc | Agonistas del receptor de trombopoyetina. |
| WO2006110626A1 (en) * | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
| CN101155792A (zh) * | 2005-04-12 | 2008-04-02 | 默克公司 | 氨基丙氧基苯基增食欲素受体拮抗剂 |
| JP2006328057A (ja) * | 2005-04-25 | 2006-12-07 | Eisai R & D Management Co Ltd | 抗不安薬及びそのスクリーニング方法 |
| UA93903C2 (ru) | 2006-03-15 | 2011-03-25 | Актелион Фармасьютикалз Лтд | Производные тетрагидроизохинолина для повышения функции памяти |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| AU2007296301A1 (en) | 2006-09-11 | 2008-03-20 | Glaxo Group Limited | Azabicyclic compounds as inhibitors of monoamines reuptake |
| JP2010504957A (ja) * | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| KR20100075444A (ko) | 2007-09-21 | 2010-07-02 | 사노피-아벤티스 | （사이클로프로필－페닐）－페닐－옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도 |
| PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
| TW201033190A (en) * | 2008-12-02 | 2010-09-16 | Glaxo Group Ltd | Novel compounds |
| US20120165339A1 (en) * | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
-
2011
- 2011-09-20 AR ARP110103428A patent/AR083060A1/es active IP Right Grant
- 2011-09-20 EP EP11826816.8A patent/EP2626350B1/en active Active
- 2011-09-20 NZ NZ609313A patent/NZ609313A/en unknown
- 2011-09-20 TW TW100133754A patent/TWI516484B/zh active
- 2011-09-20 MX MX2013003218A patent/MX2013003218A/es active IP Right Grant
- 2011-09-20 ES ES11826816.8T patent/ES2540851T3/es active Active
- 2011-09-20 KR KR1020137009631A patent/KR101458007B1/ko active IP Right Grant
- 2011-09-20 PT PT118268168T patent/PT2626350E/pt unknown
- 2011-09-20 SI SI201130507T patent/SI2626350T1/sl unknown
- 2011-09-20 MA MA35823A patent/MA34609B1/fr unknown
- 2011-09-20 CN CN201180045556.7A patent/CN103153963B/zh active Active
- 2011-09-20 RS RS20150418A patent/RS54101B1/en unknown
- 2011-09-20 CA CA2811895A patent/CA2811895C/en active Active
- 2011-09-20 UA UAA201304939A patent/UA108510C2/ru unknown
- 2011-09-20 MY MYPI2013000954A patent/MY160969A/en unknown
- 2011-09-20 BR BR112013006594-0A patent/BR112013006594B1/pt active IP Right Grant
- 2011-09-20 JO JOP/2011/0289A patent/JO2990B1/ar active
- 2011-09-20 PL PL11826816T patent/PL2626350T3/pl unknown
- 2011-09-20 AU AU2011304285A patent/AU2011304285B2/en active Active
- 2011-09-20 PE PE2013000532A patent/PE20131162A1/es active IP Right Grant
- 2011-09-20 RU RU2013117464/04A patent/RU2571414C2/ru active
- 2011-09-20 SG SG2013019880A patent/SG188585A1/en unknown
- 2011-09-20 WO PCT/JP2011/071325 patent/WO2012039371A1/ja active Application Filing
- 2011-09-20 US US13/237,205 patent/US8268848B2/en active Active
- 2011-09-20 DK DK11826816.8T patent/DK2626350T3/en active
- 2011-09-20 JP JP2012500752A patent/JP4944286B1/ja active Active
-
2013
- 2013-03-21 CL CL2013000784A patent/CL2013000784A1/es unknown
- 2013-03-21 IL IL225437A patent/IL225437A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013006594A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| BR112012020311A2 (pt) | "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." | |
| MY179607A (en) | Combinations of akt inhibitor compounds and abiraterone, and methods of use | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| JO3452B1 (ar) | بنزاميدات أمينو اريل مغاير كمثبطات كيناز | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2016006199A (es) | Inhibidores de replicacion del virus de influenza. | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| BR112015024075A2 (pt) | compostos de piridinilpirazoloquinolina | |
| MX368178B (es) | Compuestos de ácido dimetilbenzoico. | |
| BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
| BR112015020222A8 (pt) | composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas | |
| IN2013MU03862A (pt) | ||
| UA109793C2 (uk) | Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс) | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| IN2013MU03565A (pt) | ||
| MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
| BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo | |
| UA82061U (uk) | Дезінфікуючий засіб |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2011, OBSERVADAS AS CONDICOES LEGAIS. |